Gastroenterology Advisor news story
Tenofovir alafenamide reduces risk for hepatocellular carcinoma (HCC) by 71% relative to tenofovir disoproxil fumarate in antiviral-naïve chronic hepatitis B (CHB), according to study findings published in Journal of Gastroenterology and Hepatology.
The data support consideration of tenofovir alafenamide, especially in subgroups at heightened HCC risk. Prospective, long-term studies are warranted to validate these findings and elucidate mechanisms by which nucleos(t)ide analog choice may influence carcinogenesis in chronic hepatitis B.
Read the full news story here.
/Gastroenterology Advisor requires free registration if more than 5 articles are viewed per month/
Source : Gastroenterology Advisor
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.